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HIGHLIGHTS 
 A novel cephalosporin with activity towards non fermenting Gram-negative 
bacteria. 
 Good in vitro antimicrobial activity against CF clinical isolates of P. aeruginosa in 
comparison to other antimicrobials. 
 No activity against B. cenocepacia and A. xylosoxidans. 
 
ABSTRACT 
INTRODUCTION. Pulmonary exacerbations in people with Cystic Fibrosis (CF), with 
chronic Gram-negative pathogens, are associated with reduced survival. These 
pathogens are usually treated with repeated courses of systemic antibiotics. However 
there is a linked emergence of multidrug resistant (MDR) pathogens. 
Ceftolozane/tazobactam is a new cephalosporin/beta-lactamase inhibitor 
combination that has been demonstrated to have good activity against MDR 
Pseudomonas aeruginosa. 
MATERIAL & METHODS. In this study ceftolozane/tazobactam was compared to 
other commonly used intravenous antibiotics against 193 non-fermenting Gram-
negative bacteria isolated from CF sputum specimens, including P. aeruginosa, 
Achromobacter xylosoxidans, Stenotrophomonas maltophilia and Burkholderia. MICs 
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to ceftolozane/tazobactam were determined by standard E-test assay and interpreted 
according to current EUCAST guidelines.  
RESULTS. Ceftolozane/tazobactam had good in vitro antimicrobial activity against 
CF clinical isolates of P. aeruginosa in comparison to other antimicrobials with the 
exception of colistin. Ceftolozane/tazobactam also had activity against S. maltophilia, 
but was not active against B. cenocepacia and A. xylosoxidans. 
DISCUSSION. ceftolozane/tazobactam showed excellent in vitro activity against P. 
aeruginosa from CF clinical isolates. This antibiotic is a potential therapeutic option 
when presented with challenging MDR P. aeruginosa and S. maltophilia 
exacerbations. Further clinical experience and trials in CF are required to determine 
the place of this antimicrobial in clinical practice. 
 
KEYWORDS: Ceftolozane/tazobactam; P. aeruginosa; S. maltophilia; respiratory 
infection; cystic fibrosis; antibiotic resistance.  
 
INTRODUCTION 
Pulmonary exacerbations of chronic respiratory infections significantly contribute to 
the morbidity and mortality among adults with Cystic Fibrosis (CF) [1]. These 
infections are usually dominated by non-fermenting Gram-negative bacteria (NF-
GNB), e.g. Burkholderia cenocepacia, Achromobacter xylosoxidans, 
Stenotrophomonas maltophilia and especially Pseudomonas aeruginosa [2]. 
 
Aggressive antibiotic management of acute pulmonary exacerbations has contributed 
to improvements in the median expectation of life for adults affected by CF with a 
median predicted survival of 41 years [3]. However, the repeated use of antibiotics 
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aligns with the emergence of antimicrobial resistance [4]. The persistence of MDR 
bacterial strains in the lung is associated with poorer clinical outcomes [3].  
Ceftolozane/tazobactam is a new extended-spectrum beta-lactam/beta-lactamase 
inhibitor combination approved by the European Medicines Agency (EMA) for the 
treatment of complicated urinary and intra-abdominal infections in adults [5].  
 
Ceftolozane has a similar mechanism of action to other cephalosporin antibiotics. 
The addition of tazobactam increases the activity of this combination to include 
several extended-spectrum beta-lactamase-producing bacteria [6]. This new 
compound has demonstrated promising results in comparison with other beta-
lactams against P. aeruginosa strains with various resistance patterns in non-CF 
isolates [7]. The purpose of this study was to evaluate the in vitro antibacterial activity 
of ceftolozane/tazobactam against P. aeruginosa and other NF-GNB isolates from 
CF patients. 
 
METHODS   
This study was performed on an anonymized historical collection of non-duplicated 
bacterial isolates from patients with CF attending the Northern Ireland Regional Adult 
CF Centre, Belfast City Hospital, UK. One hundred and twenty P. aeruginosa 
isolates, 34 S. maltophilia isolates and 39 B. cenocepacia isolates were recovered 
from CF sputum specimens between January 2001 to December 2010 
(www.microark.com). P. aeruginosa reference strain NCTC 10662 was also included. 
Minimum inhibitory concentration (MIC) to ceftolozane/tazobactam for each isolate 
was determined by standard E-test assay based on the manufacturer's 
recommendations [8]. The results were interpreted according to current EUCAST 
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guidelines [9]. A clinical breakpoint of 4 mcg/mL was employed for P. aeruginosa. 
However as no species-specific breakpoint is currently available for other NF-GNB, 
the same breakpoint of ≤4mcg/mL was used. 
 
Susceptibilities for all others antimicrobials were determined by the modified Bauer–
Kirby disc diffusion methodology following the EUCAST criteria [9]. Comparator 
antimicrobials were piperacillin/tazobactam (30/6 mcg), aztreonam (30 mcg), 
ceftazidime (30 mcg), meropenem (10 mcg), ciprofloxacin (5 mcg), tobramycin (10 
mcg) and colistin (10 mcg). Testing of trimethoprim/sulphamethoxazole (25 mcg) and 
minocycline (30 mcg) were added for S. maltophilia and B. cenocepacia isolates. 
MDR was defined as acquired non-susceptibility to at least one agent in three or 
more antimicrobial classes, XDR was defined as susceptibility to only one or two 
categories and pan-Resistant was defined as non-susceptibility to all agents in all 
antimicrobial classes [10]. 
RESULTS 
The median MIC for ceftolozane/tazobactam against P. aeruginosa was 1.5 mcg/mL; 
MIC50 and MIC90 were 1.5 mcg/mL and 8 mcg/mL, respectively. A total of 101/120 
(84.2%) P. aeruginosa clinical isolates were sensitive to ceftolozane/tazobactam and 
in only two cases isolates were highly resistant (MIC >256).  The percentage of 
resistant P. aeruginosa isolates for ceftolozane/tazobactam and other antimicrobial 
comparators is reported in Figure 1.  
In this collection of strains, percentage of resistance for ceftolozane/tazobactam were 
lower than those for piperacillin/tazobactam, meropenem and aztreonam (Figure 1). 
In particular, ceftolozane/tazobactam was effective in most of meropenem-resistant 
P. aeruginosa isolates (20/34, median MIC 3).  
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Ceftolozane/tazobactam median MICs were significantly higher in ceftazidime and 
meropenem resistant isolates in comparison to susceptible isolates (p=0.003 and 
0.013, respectively); in particular, the 57/71 (80.3%) ceftazidime-resistant isolates 
were sensitive to ceftolozane/tazobactam, whilst all the isolates resistant to 
ceftolozane/tazobactam (n= 14) were also resistant to ceftazidime. Antibiotic 
resistance among P. aeruginosa (defined as both MDR and XDR isolates) was 
observed in 51 isolates (42.5%), while pan-resistant isolates were 3 (2.5%).  
Ceftolozane/tazobactam median MIC in P. aeruginosa isolates increased markedly 
as the number of resistant antibiotic classes increased (Table 1). 
 
The median MIC for ceftolozane/tazobactam against S. maltophilia was 1.75 mcg/ml; 
MIC50 and MIC90 were 1.5 mcg/ml and >256 mcg/ml, respectively. A specific clinical 
breakpoint for S. maltophilia has not been validated yet. However assuming a value 
of ≤4 mcg/mL, 20/34 (58.8%) of CF isolates were susceptible to 
ceftolozane/tazobactam. The percentage of isolates within the susceptible range for 
other antibiotics was as follows: 1/34 (2.9%) for ceftazidime, 27/34 (79.4%) for 
levofloxacin, 22/34 (64.7%) for trimethoprim/sulfamethoxazole and 31/34 (91.2%) for 
minocycline. 
 
A. xylosoxidans and B. cenocepacia were resistant to ceftolozane/tazobactam 
(median MICs were 32 mcg/ml and >256 mcg/ml for A. xylosoxidans and B. 
cenocepacia, respectively) as well as to all the others antimicrobial comparators  
 
DISCUSSION 
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This study demonstrates that ceftolozane/tazobactam has the lowest percentage of 
in-vitro antimicrobial resistances against P. aeruginosa within the beta-lactam group. 
In P. aeruginosa strains ceftolozane/tazobactam resistance was less than for the 
majority of antimicrobials, including aminoglycosides and fluoroquinolones. Only 
colistin had a better in vitro performance. Ceftolozane/tazobactam is a new 
antipseudomonal compound and not yet widely used in CF. A recent case report 
demonstrated the first successful use of ceftolozane/tazobactam to treat an acute 
respiratory exacerbation of CF caused by MDR P. aeruginosa [11, 12]. Our CF 
related-data is in agreement with previously published non-CF data [13], 
demonstrating that ceftolozane/tazobactam was active in the majority of meropenem-
resistant P. aeruginosa isolates. 
 
A subanalysis for P. aeruginosa showed that MICs for ceftolozane/tazobactam were 
higher as isolates became resistant to one, two or more antimicrobial classes. All 
isolates resistant to all antimicrobial classes, including colistin, were also resistant to 
ceftolozane/tazobactam. These results suggest that resistance mechanisms for 
ceftolozane/tazobactam may already exist in MDR isolates and such mechanisms 
are probably shared with other antibiotics.  
 
Antimicrobial resistance to common beta-lactams in S. maltophilia was consistent 
with data published for non-CF patients [14]. However, it is encouraging to note 
ceftolozane/tazobactam performed well against Stenotrophomonas with almost 60% 
of isolates susceptible at a surrogated clinical breakpoint. In contrast  
ceftolozane/tazobactam had little in vitro effect  against other NF-GNB such as B. 
cenocepacia and A. xylosoxidans. 
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This is the largest sample of NF-GNB tested for ceftolozane/tazobactam and the data 
suggests that it has a role in the treatment of P. aeruginosa resistant to commonly 
used beta-lactams and S. maltophilia isolates. Additionally, this is the first study to 
perform antibiotic susceptibility testing of ceftolozane/tazobactam on B. cenocepacia 
isolates confirming the highly resistant pattern of this group of bacteria. 
 
The most notable limitation of this study is the  data was generated from a single 
centre. Further large-scale studies including clinical NF-GNB isolates from different 
centres/countries are warranted to further corroborate our findings.  
This collection of isolates dates back to the period 2001-2010 and the percentage of 
resistant pathogens may have changed since this epoch.  
Our results should be interpreted under the understanding that : 1) the susceptibility 
profiles studied here may not reflect the in vivo activity in patients with CF, since 
microorganisms tested may be in a biofilm-mode of growth and we are not able to 
report any differences between mucous versus non-mucous strains; 2) the current 
clinical breakpoint for ceftolozane/tazobactam is calculated for abdominal or 
complicated urinary tract infections in non-CF population. A definite breakpoint for P. 
aeruginosa isolated from CF sputum as well as other non-fermenting pathogens has 
not been determined as yet.  
Lastly, although microdiffusion is usually preferred to test MIC for colistin, in this 
study MIC values have been obtained following disc diffusion methodology. 
 
In conclusion, ceftolozane/tazobactam showed excellent in vitro activity against P. 
aeruginosa from CF clinical isolates. This antibiotic is a potential therapeutic option 
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when presented with challenging MDR P. aeruginosa and S. maltophilia 
exacerbations. Further clinical experience and trials in CF are required to determine 
the place of this antimicrobial in clinical practice. 
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Figure 1: Percentage of Pseudomonas aeruginosa isolates resistant to 
ceftolozane/tazobactam and other commonly used anti-pseudomonal 
antibiotics. 
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Table 1 – Antibiotic susceptibility of Pseudomonas aeruginosa isolates to ceftolozane/tazobactam according 
to resistance to other antimicrobials 
Pseudomonas aeruginosa isolates MIC (range) [mcg/mL] 
MDR Pseudomonas isolates (n=29) 1.5 (0.75 - >256) 
XDR Pseudomonas isolates (n=22) 3.5 (0.75 - >256) 
Pan-Resistant Pseudomonas isolates (n=3) 256 (>256 - >256) 
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